Ефективність впливу мінеральної добавки на продуктивність та гематологічні показники мʼясних перепелів

The mineral elements contained in poultry feed do not fully meet their needs. Therefore, the elements that are lacking in the diet are introduced into the feed or feed mixtures to ensure mineral integrity. The aim of the experiment was to research the cobalt chelate complex effect on live weight, weight gain, slaughter quality and hematological parameters of Pharaoh quails.Scientific studies of the cobalt chelate complex effect on quail productivity were conducted on a research farm of Vinnytsia National Agrarian University. Two 20-bird groups were formed on the principle of analogues. The experiment lasted for 42 days, i.e., equalization period lasted for five days, and the main period lasted for 37 days.Control slaughter was performed at the end of the experiment, four heads from each group were slaughtered to determine the main indicators of slaughter and blood. The quails additionally fed by the cobalt chelate complex outnumbered their control counterparts in life weight, i.e., females by 8.5 % (P ≥ 0.001) and males by 7.9 % (P ≥ 0.001).Feeding supplements increases the absolute increase by 8.5 % (P ≥ 0.001) in female quails and by 8.1 % (P ≥ 0.001) in male quails of group II than in the control group.Due to the action of the cobalt chelate complex in group ІІ, feed consumption per 1 kg of growth is reduced in females by 6.62 % and males by 6.12 % relative to control counterparts.In group ІІ, the pre-slaughter live weight of quails increased by 7.7 % (P ≥ 0.05), the gutted carcass increased by 8.1 % (P ≥ 0.05) and the gizzard weight increased by 7.8 % (P ≥ 0.05) than the control indicator.The cobalt chelate complexapplication increases the weight of the breast by 12.1 % (P ≥ 0.01) and thigh by 14.3 % (P ≥ 0.05) in group II relative to control analogues. In group II quails of the amount of hemoglobin increases by 7.2 % (P ≥ 0.05) under the action of the researched supplement in comparison with the control sample.Мінеральні елементи, що містяться в кормах для птиці, не повною мірою забезпечують їх потреби. Тому для забезпечення мінеральної повноцінності до складу комбікормів або кормосумішей вводять елементи, яких не вистачає в раціоні. Тому метою досліду було вивчити вплив халатного комплексу Кобальту на живу масу, прирости, забійні якості та гематологічні показники перепелів м’ясної породи “Фараон”. Наукові дослідження з впливу хелатного комплексу кобальту на продуктивність перепелів проводили в умовах науково-дослідної ферми Вінницького національного аграрного університету. За принципом аналогів було сформовано дві групи птиці по 20 голів у кожній. Дослідження тривали 42 доби, з них 5 діб зрівняльний період, 37 доби – основний. У кінці досліду був проведений контрольний забій – по 4 голови з кожної групи та визначали основні показники забою та крові. Встановлено, що перепели, які додатково використовували халатний комплекс Кобальту, переважили за живою масою своїх ровесників з контролю, самиці на 8,5 % (P ≥ 0,001) та самці на 7,9 % (P ≥ 0,001). Застосування кормової добавки підвищує у перепелів 2-ї групи абсолютний приріст у самиць на 8,5 % (P ≥ 0,001) та у самців на 8,1 % (P ≥ 0,001), проти контрольної групи. Виявлено, що у птиці 2-ї групи за дії халатного комплексу кобальту знижуються витрати корму на 1 кг приросту самиць на 6,62 % та самців на 6,12 % щодо контрольних ровесників. Зафіксовано, що за дії досліджуваної добавки збільшується передзабійна жива маса перепелів 2-ї групи на 7,7 % (P ≥ 0,05), патраної тушки на 8,1 % (P ≥ 0,05) та маса м’язового шлунку на 7,8 % (P ≥ 0,05) щодо контрольного показника. Виявлено, що застосування халатного комплексу Кобальту в перепелів 2-ї групи підвищує масу грудних на 12,1 % (P ≥ 0,01) та стегнових на 14,3 % (P ≥ 0,05) щодо контрольних аналогів. За дії досліджуваної добавки у перепелів 2-ї групи збільшується кількість гемоглобіну на 7,2 % (P ≥ 0,05) щодо контрольного зразка

Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease

BACKGROUND We evaluated whether rivaroxaban alone or in combination with aspirin would be more effective than aspirin alone for secondary cardiovascular prevention. METHODS In this double-blind trial, we randomly assigned 27,395 participants with stable atherosclerotic vascular disease to receive rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg once daily), rivaroxaban (5 mg twice daily), or aspirin (100 mg once daily). The primary outcome was a composite of cardiovascular death, stroke, or myocardial infarction. The study was stopped for superiority of the rivaroxaban-plus-aspirin group after a mean follow-up of 23 months. RESULTS The primary outcome occurred in fewer patients in the rivaroxaban-plus-aspirin group than in the aspirin-alone group (379 patients [4.1%] vs. 496 patients [5.4%]; hazard ratio, 0.76; 95% confidence interval [CI], 0.66 to 0.86; P<0.001; z=−4.126), but major bleeding events occurred in more patients in the rivaroxaban-plus-aspirin group (288 patients [3.1%] vs. 170 patients [1.9%]; hazard ratio, 1.70; 95% CI, 1.40 to 2.05; P<0.001). There was no significant difference in intracranial or fatal bleeding between these two groups. There were 313 deaths (3.4%) in the rivaroxaban-plus-aspirin group as compared with 378 (4.1%) in the aspirin-alone group (hazard ratio, 0.82; 95% CI, 0.71 to 0.96; P=0.01; threshold P value for significance, 0.0025). The primary outcome did not occur in significantly fewer patients in the rivaroxaban-alone group than in the aspirin-alone group, but major bleeding events occurred in more patients in the rivaroxaban-alone group. CONCLUSIONS Among patients with stable atherosclerotic vascular disease, those assigned to rivaroxaban (2.5 mg twice daily) plus aspirin had better cardiovascular outcomes and more major bleeding events than those assigned to aspirin alone. Rivaroxaban (5 mg twice daily) alone did not result in better cardiovascular outcomes than aspirin alone and resulted in more major bleeding events. (Funded by Bayer; COMPASS ClinicalTrials.gov number, NCT01776424.

Rivaroxaban with or without aspirin in stable cardiovascular disease

BACKGROUND: We evaluated whether rivaroxaban alone or in combination with aspirin would be more effective than aspirin alone for secondary cardiovascular prevention. METHODS: In this double-blind trial, we randomly assigned 27,395 participants with stable atherosclerotic vascular disease to receive rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg once daily), rivaroxaban (5 mg twice daily), or aspirin (100 mg once daily). The primary outcome was a composite of cardiovascular death, stroke, or myocardial infarction. The study was stopped for superiority of the rivaroxaban-plus-aspirin group after a mean follow-up of 23 months. RESULTS: The primary outcome occurred in fewer patients in the rivaroxaban-plus-aspirin group than in the aspirin-alone group (379 patients [4.1%] vs. 496 patients [5.4%]; hazard ratio, 0.76; 95% confidence interval [CI], 0.66 to 0.86; P<0.001; z=−4.126), but major bleeding events occurred in more patients in the rivaroxaban-plus-aspirin group (288 patients [3.1%] vs. 170 patients [1.9%]; hazard ratio, 1.70; 95% CI, 1.40 to 2.05; P<0.001). There was no significant difference in intracranial or fatal bleeding between these two groups. There were 313 deaths (3.4%) in the rivaroxaban-plus-aspirin group as compared with 378 (4.1%) in the aspirin-alone group (hazard ratio, 0.82; 95% CI, 0.71 to 0.96; P=0.01; threshold P value for significance, 0.0025). The primary outcome did not occur in significantly fewer patients in the rivaroxaban-alone group than in the aspirin-alone group, but major bleeding events occurred in more patients in the rivaroxaban-alone group. CONCLUSIONS: Among patients with stable atherosclerotic vascular disease, those assigned to rivaroxaban (2.5 mg twice daily) plus aspirin had better cardiovascular outcomes and more major bleeding events than those assigned to aspirin alone. Rivaroxaban (5 mg twice daily) alone did not result in better cardiovascular outcomes than aspirin alone and resulted in more major bleeding events